Globus Medical’s world is about to get a little bigger, as the orthopedic devicemaker moves to acquire Nevro and its ...

GlobalData senior medical device analyst says the acquisition could see Nevro’s growth outside the US accelerate.

Analysts said Nevro’s valuation was “inexpensive,” but the spinal cord stimulation business can benefit from Globus’ scale ...

Nevro Corp is a medical device company. Its key product is the HFX spinal cord stimulation (SCS ... It consists of leads, a trial stimulator, an implantable pulse generator, surgical tools ...

Nevro, with its HFXTM spinal cord stimulation device, should gain from Globus' operational scope and worldwide infrastructure. While Nevro recorded income of around $408 million, Globus Medical's ...

Boosting communication between the spinal nerves and the muscles using the spinal cord stimulation reverses spinal muscle ...

Nevro Corp. NVRO recently received CE Mark Certification in Europe for its HFX iQ spinal cord stimulation (SCS) system. The company can now market HFX iQ in all countries that recognize this ...

Jan. 22, 2015 /PRNewswire/ -- Nevro Corp. (NYSE ... of its Premarket Approval Application (PMA) for the Senza spinal cord stimulation (SCS) system. According to the approvable letter, approval ...

Spinal Cord Stimulators Market. The global spinal cord stimulators market is on an accelerated growth path, projected to ...

Nevro said revenue is higher primarily due to the effect of greater-than-anticipated spinal cord stimulation device replacement procedures in the fourth quarter of 2024. Cash, cash equivalents and ...

Globus Medical plans to buy spinal cord stimulation company Nevro for about $250 million, the companies announced on Thursday. Globus will pay $5.85 per share in an all-cash purchase, a 27% ...